The Government, in its response to the House of Commons Select Committee inquiry on the National Institute for Health and Clinical Excellence, agrees that the issue of how NICE takes account of wider measurements in arriving at an assessment should be debated.
Discussion to explore the issue in more detail with key stakeholders, including the NHS, patient representatives and the pharmaceutical industry are proposed, and the ABPI looks forward to participating.
“The price paid for a medicine or any other treatment has to be seen in the context of the overall value it brings – including benefits such as savings in hospital care and social services as well as quality of life improvements for patients,” said David Fisher, Commercial Director at the ABPI.
“NICE’s decisions have been made on far too narrow a basis, with the result that many innovative medicines have not been made available to all patients who could benefit from them. We shall eagerly participate in these discussions with the aim of putting that right.”
For further information, please contact: ABPI Press office 020 7747 1410